3Heidland A, Sebekova K, Schinzel R. Advanced glycation end productsand the progressive course of renal disease[ J]. Kidney Dis,2001,38 ( suppl) : 100 - 106.
4Schrijvers BF, De Vriese AS. Novel insights in the treatment of diabetic nephropathy[ J]. Acta Clin Belg. 2007,62(5) :278 - 290.
5Candido R, Allen TJ,Lassila M,et al. Irbesartan but not amlodipine sup - presses diabetes - associated atherosclerosis [ J ]. Circulation, 2004, 109(12) :1536 - 1542.
6Mogensen CE. The diabetic kidney: from hyperfiltration and microalbuminutia to end - stage renal failure[ J]. Med Clin North Am, 1988,72 (6) :1465 - 1492.
7McMurray S, Johnson G, Davis S, et al. Diabetes education and care management significantly improve patient outcomes in the dialysis unit [J]. Kidney Dis, 2002, 40(3):566 -575.
8Fisman EZ, Tenebaum A, Motro M. Losartan and diabetic nephropathy: commentaries on the RENAAL study [ J ]. Cardiovascular Diabetol, 2002, 1(1) :2.
9Young BA,Johnson RJ, Alpers CE, et al. Cellular events in the evolution of experiment.,d diabetic nephrnpathy [ J ]. Kidney lnt, 1995,47 ; 935 - 944.
